{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "IMRN",
  "name": "Immuron Limited",
  "url": "https://frontierpicks.com/dossiers/IMRN/",
  "json_url": "https://frontierpicks.com/dossiers/IMRN.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a6",
    "n": 6
  },
  "current_thesis": "Clinical-stage biotech repriced as a consumer gut-health distributor: the 2026-09-04 exclusive US deal with Calmino for PROIBS took an ~$8.9M-market-value ADR up 48.2% intraday, eight sessions after FY26 record sales of A$7.7M and cash of A$9.0M (2026-08-28). No deal economics and no launch date were disclosed, leaving an accelerating narrative with no company-confirmed catalyst inside 30 days.",
  "invalidation_trigger": "A weekly close below $1.65 hands back the 2026-09-04 announcement advance and leaves no structure above the pre-deal range; secondarily, the FY26 annual report landing around 2026-09-30 with PROIBS economics and launch timing still undisclosed.",
  "catalyst_date": "2026-09-30",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "binary-catalyst-biotech",
    "managed-care-health-services",
    "small-cap-value-rotation"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Primary listing is ASX:IMC; the Nasdaq line is an ADR, so US sessions open onto an overnight Australian print.",
    "Reports in Australian dollars against a 30 June fiscal year end; FY26 ended 2026-06-30 and the Appendix 4E preliminary was lodged 2026-08-28.",
    "Foreign private issuer: half-yearly reporting via 6-K, no US 10-Q, so there is no quarterly earnings date to anchor the tape.",
    "Market value was reported at $8.9M during the 2026-09-04 session (Benzinga); StockTitan displayed float at 8.07M shares. Institutional and index participation is minimal at that size.",
    "Equity was drawn through H.C. Wainwright & Co. In three tranches between 2025-10-20 and 2025-12-05, disclosed in a 6-K dated 2026-01-12."
  ],
  "body_markdown": "## Current Thesis\nImmuron is being repriced from a clinical-stage biotech into a consumer digestive-health distributor. The FY26 preliminary report released 2026-08-28 showed record net sales of A$7.7M (+6% YoY), a net profit improvement of A$1.4M over FY25, and cash up A$6.2M to A$9.0M — this from a company that decided in February 2026 to stop funding IMM-124E and IMM-529 itself and partner them out instead. On 2026-09-04 it signed an exclusive US distribution agreement with Sweden's Calmino group AB for PROIBS, a product launched in Australia during FY26; the ADR traded up 48.2% intraday to $1.65 on a market value Benzinga put at $8.9M that session, and finished the day at $1.80. What the release did not contain: any financial term of the agreement, and any launch date. The narrative is accelerating — two company events landed inside eight sessions and 2026-09-04 was the first session the ticker appeared on three separate mover screens — but acceleration built on one undated, unpriced agreement is thin, and no company-confirmed event sits inside the next 30 days to extend it.\n\n## Bull Case\n- FY26 net sales A$7.7M, +6% YoY, with Australia A$5.8M (+10%) and the US A$1.8M (+7% in A$, +13% in USD) — FY26 preliminary results, 2026-08-28. The growth is in the two channels that carry the group.\n- Cash of A$9.0M at 2026-06-30, up A$6.2M across FY26, against a US-dollar market value of $8.9M reported during the 2026-09-04 session (Benzinga). The two figures are different currencies on different dates, but the order of magnitude explains why a single distribution headline moved the equity ~50% in a day.\n- The February 2026 decision to partner IMM-124E and IMM-529, and the July 2026 engagement of Pullan Consulting for IMM-529, shifts trial spend off the company's own funding. IMM-529 holds an FDA-approved IND and was described on 2026-08-28 as ready to enter Phase 2 — a partnering event would be free optionality on top of the consumer business.\n- PROIBS adds a second consumer line onto sales infrastructure that already exists. The 2026-09-04 release cited an Australian usability study of 1,003 users in which 94% found the product helpful, 91% reported improved daily life and 98% would recommend it.\n- The same release cited Mordor Intelligence sizing the US digestive/gut-health supplement market at $4.16bn, against FY26 US sales of A$1.8M.\n\n## Bear Case\n- The 2026-09-04 release disclosed no upfront, no margin, no minimum purchase, no term and no launch timetable. Nothing in FY27 revenue is yet attributable to the agreement.\n- Immuron issued 55,100,920 ordinary shares in three drawdowns dated 2025-10-20, 2025-11-07 and 2025-12-05, priced at $0.0886, $0.0756 and $0.0791 per share through H.C. Wainwright & Co., disclosed in a 6-K dated 2026-01-12 and referencing approximately US$2.85M gross under the 2025-10-06 supplementary prospectus. A company that drew equity three times in ten weeks has a live channel for supplying stock into strength.\n- Canadian sales fell 55% to A$0.2M in FY26 — a distribution channel going backwards inside the same report that showed record group revenue. Signing a distributor is not the same as selling through one.\n- H1 FY26 commentary attributed Australian growth of 10% to performance \"despite a one-off inventory reduction by Chemist Warehouse/Sigma\", which names the concentration in a single retail group.\n- Group revenue grew 6% in FY26. The 2026-09-04 session repriced the equity by roughly half. The distance between those two numbers is expectation.\n- RSI(14) stood at 80.8 on the 2026-09-04 close, and the FY26 print that preceded the deal was already eight sessions old.\n\n## Setup & Price Structure\nLast completed daily close $1.80 on 2026-09-04, 23.4% below the $2.35 52-week high, with the shares up 50% over three months and RSI(14) at 80.8. Everything above the $1.65 mid-session print is two sessions old, and no shelf sits beneath it because the level did not exist before the announcement. Pre-market on 2026-09-04 printed $1.83, +64.9%, above where the shares closed — the strongest bid of the day arrived before the cash open, in a name whose float StockTitan displayed at 8.07M shares. The $2.35 52-week high is the nearest overhead reference and the move stalled 23.4% under it. No base has formed; the first structural question is whether the deal-day range holds at all.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-09-30 (est.)** — FY26 annual report lodgement. ASX rules call for the audited annual report within three months of a 30 June balance date, and the Appendix 4E preliminary went out 2026-08-28. Statutory window, not a company-confirmed date; the audited document carries the auditor's opinion and segment detail the preliminary did not.\n- **~2026-10-31 (est.)** — Q1 FY27 quarterly update, outside the 30-day window. The 2026-08-28 FY27 framing placed Travelan growth in Q1, portfolio expansion in Q2 and IMM-529 partnering progress in Q3.\n- **None**\n\n## Elapsed catalysts\n\n- **Undated** — PROIBS US launch. The 2026-09-04 release gave no timetable. A launch date, a price point or a named US retail channel would be the first hard datapoint behind the story. *(passed 2d ago)*\n\n## What Would Change Our Mind\nThe structure that has to hold is the 2026-09-04 announcement range itself, because nothing beneath it was built before 2026-09-04. A weekly close below $1.65 hands back the deal-day advance and returns the shares to the pre-announcement zone, dating the episode as a one-session repricing rather than a re-rating. Second, if the annual report lands around 2026-09-30 and the Calmino agreement still carries no disclosed economics and no launch date, the story loses its only forward hook and the theme turns saturated as the mover screens move on. Third, a fresh equity issue announced after 2026-09-04 through the channel used for the October–December 2025 drawdowns would confirm supply arriving into strength. Running the other way: a disclosed launch date with a named US retailer, or an FY27 half-year showing PROIBS as an identified revenue line, would extend the leg past the headline — and an IMM-529 partnering announcement would add a second, independent narrative the current price does not carry.\n\n## Correlation Notes\n- The Binary-catalyst biotech cluster (six names: FRNM, ALVO, TARS, NVAX, INBX) reads as accelerating as of 2026-09-06, after alternating with maturing since 2026-07-07. IMRN belongs to that group by market value and volatility rather than by mechanism — its move came from a distribution contract, not a data readout — so a cluster-wide readout calendar does not carry this name, and a cooling cluster would remove a bid rather than a thesis.\n- Same-session microcap tape: Akanda (AKAN) rose 27.52% pre-market on 2026-09-04 alongside IMRN's 64.9% (Benzinga). The bid was broad across small healthcare names that morning, which is a flow condition rather than a company one.\n- Currency: revenue and cash are reported in Australian dollars while the listed line is a US ADR. FY26 US sales rose 7% in A$ and 13% in USD (2026-08-28), so reported and translated growth diverge with AUD/USD.\n- Listing: the primary listing is ASX:IMC. The US session opens onto an overnight Australian print, so gaps form outside US hours.\n- No broker estimate revisions or published price targets surfaced in the coverage reviewed for this note.",
  "first_seen": "2026-09-06",
  "last_analyzed": "2026-09-06T11:15:43+00:00",
  "last_synthesized": "2026-09-06",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}